



February 8, 2023

VIA EMAIL: AGO.highcostprescriptiondrugs@vermont.gov

Office of the Vermont Attorney General

RE: Notification of New Drug Launch

To Whom It May Concern,

Baxter Healthcare Corporation (“Baxter”) is writing to notify the Office of the Vermont Attorney General of the below-referenced drug launch pursuant to 18 V.S.A. § 4637, as the drug price exceeds the wholesale acquisition cost threshold set for a specialty drug under the Medicare Part D program.

National Drug Code	Product Description	First Sale Date	WAC Price (Each)
10019-0079-01	Bendamustine	2/8/2023	\$2,340.00

Baxter will provide all other required information referenced under 18 V.S.A. § 4637(c) within the designated time period. Should you have any questions, please do not hesitate to contact me at the email below.

Kristen Black
Sr. Manager, Government Price Reporting
E-mail: Kristen.Black@Baxter.com